Skip to content
Screener

Alumis Inc. ALMS Net margin

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
18.9%+8.4pp
Amgen logo
AmgenAMGN
23%+4.0pp
Immunome logo
ImmunomeIMNM
-5,593.8%-11,284pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-7,965.8%-10,750pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
11.1%+10.0pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-921.5%+161pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×—

Profitability

See full
Operating margin-5,364%—
FCF margin-4,487.4%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

net income/total revenue=-2,825.7%

Based on trailing twelve months.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s net margin?
Alumis Inc. (ALMS) reported net margin of -2,825.7% in Q1 2026.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.

Ask your AI about Alumis Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude